Jeffrey Lawrence Schwartz - 19 May 2022 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role: Director
Signature: /s/ Jeffrey Schwartz
Issuer symbol: SWTX
Transactions as of: 19 May 2022
Net transactions value: $0
Form type: 4
Filing time: 20 May 2022, 18:23:23 UTC
Previous filing: 16 Jul 2021
Next filing: 10 Jun 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SWTX	Common Stock	Award	$0	+4,818	+436%	$0.000000	5,924	19 May 2022	Direct	F1
holding	SWTX	Common Stock						4,831,307	19 May 2022	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SWTX	Stock Option (Right to Buy)	Award	$0	+15,318		$0.000000	15,318	19 May 2022	Common Stock	15,318	$35.42	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date.
F2	This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The options will vest in full on the earlier of (1) May 19, 2023 and (2) the Issuer's next annual meeting of stockholders, subject to continued service to the Issuer on the vesting date.
F3	Represents shares of common stock held directly by BC SW, LP. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of BC SW, LP. Mr. Schwartz is a managing director of BCLSI. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC SW, LP. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.